Ontario Tightens Rules on Funding Overseas Cancer Treatments After Court Victory
Ontario changed its policy to fund only drugs already covered provincially when used abroad, after a court ruling in a melanoma patient’s case, announced by Health Minister Sylvia Jones.
Alex Shved, a 37-year-old father with Stage 4 melanoma, challenged Ontario Health Insurance Plan after it refused to cover tumour-infiltrating lymphocyte therapy in Florida, a procedure costing roughly US$600,000. The province argued that financing such treatments abroad would weaken incentives for drug manufacturers to participate in Canada’s review process. A Divisional Court ruled the justification insufficient and ordered OHIP to reconsider.
Following the decision, OHIP rejected Shved’s request a third time and Health Minister Sylvia Jones announced a regulatory change stating that only drugs already funded in Ontario, but temporarily inaccessible, may be covered overseas. Jones added the government is working toward a mutually satisfactory resolution for Shved’s individual case.
Why it matters
The ruling reshapes Ontario's drug funding policy, affecting access to experimental cancer therapies for patients seeking treatment abroad.
In this story
